Page 106 - 《中国药房》2026年2期
P. 106

·循证药学·


          白芍总苷制剂治疗系统性红斑狼疮有效性及安全性的Meta分析
                                                                                                            Δ

                                                                    2
                                            3
                                   2 #
                                                            4
                           2
                 1*
                                                    2
          郝祥彦 ,冷家会 ,刘正奇 ,王新昌 ,黄 聪 ,李霄鹏 ,凌 益(1.贵州中医药大学研究生院,贵阳 550002;
          2.贵州中医药大学第二附属医院风湿免疫科,贵阳 550002;3.浙江中医药大学附属第二医院风湿免疫科,
          杭州 310005;4.浙江中医药大学附属第二医院科研科,杭州 310005)
          中图分类号  R979.5      文献标志码  A      文章编号  1001-0408(2026)02-0232-06
          DOI  10.6039/j.issn.1001-0408.2026.02.17

          摘   要  目的  评价白芍总苷(TGP)制剂治疗系统性红斑狼疮(SLE)的有效性及安全性。方法  检索 PubMed、Embase、Cochrane
          Library、Web of Science、中国知网、维普网、万方数据和中国生物医学文献数据库,收集TGP制剂联合西药对比单用西药的随机对
          照研究(RCT)。检索时间为建库起至2025年6月1日。筛选文献、提取资料、评价文献质量后,采用RevMan 5.4软件进行Meta分
          析。结果  共纳入15项RCT,包括1 318例患者。Meta分析结果显示,与单用西药比较,TGP制剂联合西药能提高患者的临床有效
          率[OR=4.96,95%CI(3.41,7.23),P<0.000 01]、补体 3[MD=0.18,95%CI(0.13,0.23),P<0.000 01]、补体 4 水平[MD=0.08,
          95%CI(0.04,0.11),P<0.000 01],降低免疫球蛋白G(IgG)[MD=-3.10,95%CI(-3.59,-2.62),P<0.000 01]、IgA[MD=-0.68,
          95%CI(-0.78,-0.58),P<0.000 01]、IgM[MD=-0.43,95%CI(-0.53,-0.34),P<0.000 01]、系统性红斑狼疮疾病活动性指数
          [MD=-1.59,95%CI(-2.20,-0.99),P<0.000 01]、复发率[OR=0.23,95%CI(0.13,0.42),P<0.000 01]及不良反应发生率[OR=
          0.54,95%CI(0.36,0.82),P=0.004]。结论  TGP制剂能提高SLE患者的疗效,促进免疫球蛋白及补体恢复,降低系统性红斑狼疮
          疾病活动性指数和复发率,且安全性较好。
          关键词  系统性红斑狼疮;白芍总苷;Meta分析;疗效;安全性

          Meta-analysis  of  the  efficacy  and  safety  total  glucosides  of  paeonia  in  the  treatment  of  systemic  lupus
          erythematosus
                                                                      3
                                      2
          HAO Xiangyan ,LENG Jiahui ,LIU Zhengqi ,WANG Xinchang ,HUANG Cong ,LI Xiaopeng ,LING Yi
                                                    2
                                                                                                             2
                        1
                                                                                     2
                                                                                                  4
         (1. Graduate School, Guizhou University of Traditional Chinese Medicine, Guiyang 550002, China;2. Dept. of
          Rheumatology  and  Immunology,  the  Second  Affiliated  Hospital  of  Guizhou  University  of  TCM,  Guiyang
          550002,  China;  3.  Dept.  of  Rheumatology  and  Immunology,  the  Second  Affiliated  Hospital  of  Zhejiang
          University  of  TCM,  Hangzhou  310005,  China;  4.  Scientific  Research  Department,  the  Second  Affiliated
          Hospital of Zhejiang University of TCM, Hangzhou 310005, China)
          ABSTRACT    OBJECTIVE To evaluate the efficacy and safety of total glucosides of paeonia (TGP) in the treatment of systemic
          lupus  erythematosus (SLE).  METHODS  Randomized  controlled  trial (RCT)  about  TGP  combined  with  western  medicine  versus
          western  medicine  alone  for  SLE  treatment  were  retrieved  from  PubMed,  Embase,  Cochrane  Library,  Web  of  Science,  CNKI,
          VIP,  Wanfang  Data,  and  CBM.  The  search  period  spanned  from  the  inception  of  each  database  to  June  1,  2025. After  literature
          screening,  data  extraction,  and  quality  assessment  of  the  included  studies,  Meta-analysis  was  performed  using  RevMan  5.4
          software.  RESULTS  Fifteen  RCTs,  involving  1  318  patients,  were  included.  Meta-analysis  results  showed  that  compared  with
          western  medicine  alone,  TGP  combined  with  western  medicine  significantly  improved  clinical  efficacy  [OR=4.96,  95%CI(3.41,
                                                              7.23),  P<0.000  01],  complement  3  [MD=0.18,  95%CI
              Δ 基金项目 国家重点研发计划-中医药现代化专项(No.2024-
          YFC3506100);贵州省科技计划项目(No. 黔科合成果 LC〔2025〕一          (0.13,  0.23),  P<0.000  01]  and  complement  4[MD=0.08,
          般021)                                               95%CI (0.04, 0.11), P<0.000 01], and reduced the levels of
             *第一作者 硕士研究生。研究方向:中西医结合防治风湿免疫疾
                                                              immunoglobulin  G (IgG)  [MD=-3.10,  95%CI ( -3.59,
          病。E-mail:894734003@qq.com
                                                              -2.62),  P<0.000  01],  IgA  [MD=-0.68,  95%CI (-0.78,
              # 通信作者 主任医师,硕士。研究方向:中西医结合防治风湿免
          疫疾病。E-mail:liuzhengqi130@gyz.edu.cn                 -0.58), P<0.000 01], IgM [MD=-0.43, 95%CI (-0.53,


          · 232 ·    China Pharmacy  2026 Vol. 37  No. 2                               中国药房  2026年第37卷第2期
   101   102   103   104   105   106   107   108   109   110   111